Clinical trials: Schizophrenia and Other Psychotic Disorders
Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder
SV2 PET Imaging With [11C]APP311
The aim of this study is to evaluate a new SV2A tracer, [11C]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
- Conditions
- Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
- Trial name
- SV2 (NCT03995121)
- Testing
- [11C]APP311
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Schizo Affective Disorder
iTBS to Enhance Social Cognition in People With Psychosis
The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
- Trial name
- iSCIP (NCT06118268)
- Testing
- iTBS (Active)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
Schizophrenia and Other Psychotic Disorders, Healthy Adult
Dysfunction of Respiratory Enzymes in Adults With Mental Illness (DREAM)
This study tested whether intravenous methylene blue changes brain activity during a working-memory task differently in adults with schizophrenia taking stable antipsychotic medication and healthy volunteers.
- Trial name
- DREAM (NCT07866833)
- Testing
- Methylene Blue
- Where
- United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Autism Disorder, Schizophrenia and Other Psychotic Disorders
Follow-up of Adolescents With Autism and Psychotic Symptoms - Psychiatric Co-morbidity and Functional Impairment.
Purpose: To describe level of function, psychotic and psychiatric symptoms in a 10-year follow up of individuals with autism and psychotic symptoms.
- Trial name
- NCT07427810
- Testing
- None. Observational study.
- Where
- Sweden
- Volunteers
- 53 people
- Sponsor
- Värmland County Council, Sweden
Schizophrenia
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
- Trial name
- NCT05443724
- Testing
- Emraclidine 30 mg
- Where
- 85 sites in United States, Bulgaria and 3 more
- Volunteers
- 698 people
- Sponsor
- AbbVie
Schizophrenia Spectrum and Other Psychotic Disorders, Affective Psychoses
SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study
Worries about harm from others (also known as paranoia) are common. Thinking fast or going on gut feelings is natural but can fuel these worries. For some, fast thinking and worries start to get in the way of life.
- Trial name
- NCT06568081
- Testing
- SloMo
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- King's College London
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia
Schizophrenia is a severe mental illness that seriously affects the health and functioning of patients. Previous studies have found immunoinflammatory abnormalities in the blood, cerebrospinal fluid, central nervous system, and…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders
- Trial name
- SZIM (NCT06673966)
- Testing
- Regular follow-up assessments without intervention., Cross-sectional assessment
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Central South University
Psychosis, Psychosis Nos/Other
EPI-MINN: Targeting Cognition and Motivation - National
The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using…
- Conditions
- Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT05877716
- Testing
- Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Minnesota
First Episode Psychosis
OnTrackNY's Learning Healthcare System
This application proposes OnTrackNY as a regional scientific hub for the Early Psychosis Intervention Network (EPINET) program as part of the National Institute of Mental Health (NIMH)'s creation of a national learning health…
- Trial name
- NCT04021719
- Testing
- Stakeholder feedback, Data infrastructure
- Where
- United States
- Volunteers
- 2,100 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
Although psychotic disorders typically affect less than 1% of the population, they are a significant cause of disability worldwide.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizotypal Disorder, Acute and Transient Psychotic Disorder
- Trial name
- SUCCEED (NCT06007105)
- Testing
- SUCCEED Community-Based Intervention
- Where
- 4 sites in Malawi, Nigeria and 2 more
- Volunteers
- 425 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability.
- Conditions
- Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- DREAMS-Phen (NCT07152184)
- Testing
- Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup
- Volunteers
- 288 people
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia Spectrum & Other Psychotic Disorders
REFLECT: A Novel Group-Based Compassion-Focussed Cognitive Behavioural Approach to Core Beliefs in Psychosis
The current study is an open-label, proof-of-concept, pilot trial examining the feasibility, safety, and preliminary efficacy of a 6-week group therapy intervention targeting core beliefs related to symptoms of psychosis.
- Trial name
- REFLECT (NCT07569471)
- Testing
- REFLECT: REFlecting on and Learning to Evaluate Core beliefs in real Time
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- University of Toronto
Severe Mental Illness, Schizophrenia Spectrum &Amp; Other Psychotic Disorders
Validation and Impact of Cardiorespiratory Fitness in Severe Mental Illness - the Heart in Mind Project
This project aims to evaluate feasibility, validity and clinically applicability to systematically measure fitness in patients with severe mental illness. The research project is a validation study using a cross-sectional design.
- Conditions
- Severe Mental Illness, Schizophrenia Spectrum &Amp; Other Psychotic Disorders, Bipolar Affective Disorder
- Trial name
- NCT06743711
- Where
- Denmark
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Bjorn H. Ebdrup
Schizophrenia, Acute Episode
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of elpipodect compared with placebo, using Risperidone as an active control.
- Trial name
- NCT03055338
- Testing
- Elpipodect, Risperidone
- Where
- 28 sites in United States
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia Spectrum and Other Psychotic Disorders
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce.
- Trial name
- RCT-RITS (NCT05622201)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 123 people
- Sponsor
- Region Örebro County
Psychiatric Disorders, Depression - Major Depressive Disorder
Implementing Action-Based Cognitive Remediation for Transdiagnostic Cognitive Difficulties in a Tertiary Mental Health Hospital
Psychiatric conditions are each defined by different set of symptoms, however, they often share common characteristics such as impairments in cognitive and social functioning.
- Conditions
- Psychiatric Disorders, Depression - Major Depressive Disorder, Schizophrenia and Other Psychotic Disorders, Anxiety and Mood Disorders
- Trial name
- NCT07506070
- Testing
- Action-Based Cognitive Remediation
- Volunteers
- 160 people
- Sponsor
- The Royal Ottawa Mental Health Centre